Integrated serum metabolomics reveal molecular mechanism of Xietu Hemu prescription on metabolic dysfunction-associated steatotic liver disease-related obesity

Figure 8 Inhibition of lipid synthesis by Xietu Hemu prescription following siRNA disruption of leptin receptor in 3T3-L1 cells. A and B: SiRNA disruption of 3T3-L1 cell LEPR efficiency test; C and D: Oil red O staining micro camera and statistics of difference in lipid droplet area occupation on day 10 with/without high dose of Xietu Hemu prescription (H-XHP) or siLEPR intervention; E-J: Detection and quantitative statistics of cytoplasm protein levels on day 10 with/without H-XHP or siLEPR intervention (n = 3); K-M: Detection and quantitative statistics of nucleus protein levels on day 10 with/without H-XHP or siLEPR intervention (n = 3). Data were expressed as mean ± SEM. 200 ×, 50 μm; 400 ×, 25 μm; ^aP < 0.05 vs vehicle; ^bP < 0.05 vs model-vehicle; ^cP < 0.01 vs model-vehicle; ^dP < 0.005 vs model-vehicle; ^eP < 0.001 vs model-vehicle; ^fP < 0.05 vs model-siLEPR1; ^gP < 0.01 vs model-siLEPR1;^hP < 0.001 vs model-siLEPR1; ⁱP < 0.05 vs high dose of Xietu Hemu prescription (H-XHP)-vehicle; ^jP < 0.01 vs H-XHP-vehicle; ^kP < 0.005 vs H-XHP-vehicle; ^lP < 0.001 vs H-XHP-vehicle. H-XHP: High dose of Xietu Hemu prescription.